Comparative Diagnostic Performance of Amyloid-β Positron Emission Tomography and Magnetic Resonance Imaging in Alzheimer's Disease: A Head-to-Head Meta-Analysis

被引:0
作者
Li, Fang [1 ]
Cheng, Jiang [1 ]
Jin, Kaihui [1 ]
Zhao, Li [1 ]
Li, Junyong [1 ]
Wu, Jia [1 ]
Ren, Xiaolu [2 ,3 ]
机构
[1] Ningxia Med Univ, Gen Hosp, Dept Neurol, Yinchuan, Peoples R China
[2] Ningxia Med Univ, Gen Hosp, Dept Radiol, Yinchuan, Peoples R China
[3] Univ Sains Malaysia, Sch Hlth Sci, Kubang Kerian, Kelantan, Malaysia
来源
BRAIN AND BEHAVIOR | 2024年 / 14卷 / 10期
关键词
Alzheimer's disease; amyloid-beta; magnetic resonance imaging; positron emission tomography; MILD COGNITIVE IMPAIRMENT; STRUCTURAL MRI; PET; F-18-FLUTEMETAMOL; CLASSIFICATION; PREDICTION; ACCURACY;
D O I
10.1002/brb3.70111
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Objective: This meta-analysis aimed to evaluate the comparative diagnostic performance of amyloid-beta positron emission tomography (A beta PET) and magnetic resonance imaging (MRI) in diagnosing Alzheimer's disease (AD). Methods: An extensive search was conducted in the PubMed and Embase databases to identify available publications up to December 2023. Head-to-head comparative studies were included if they evaluated the diagnostic performance of A beta PET and MRI in diagnosing Alzheimer's disease. Sensitivity and specificity were assessed using the DerSimonian and Laird method, followed by transformation via the Freeman-Tukey double inverse sine transformation. Results: Six articles involving 560 patients were included in the meta-analysis. When distinguishing AD from mild cognitive impairment (MCI), both methods showed comparable sensitivity (A beta PET: 0.71, MRI: 0.62) and specificity (A beta PET: 0.68, MRI: 0.69), with no statistically significant differences observed (p = 0.34 and 0.99). When identifying AD from normal cognitive control (NC), both A beta PET and MRI showed similar results, with comparable sensitivity (A beta PET: 0.93, MRI: 0.85) and specificity (A beta PET: 0.95, MRI: 0.82), without significant differences (p = 0.38 and 0.19). Similarly, in detecting MCI from NC, both A beta PET and MRI demonstrated similar sensitivity (A beta PET: 0.69, MRI: 0.64) and specificity (A beta PET: 0.75, MRI: 0.76) without significant differences (p = 0.40 and 0.94). However, 18F-FMM seems to have a higher specificity compared to MRI when distinguishing AD from MCI (P = 0.03) and AD from NC (p = 0.04). Conclusions: Our meta-analysis indicates that A beta PET demonstrates similar sensitivity and specificity to MRI in diagnosing Alzheimer's disease. However, the limited number of studies may impact the evidence of the current study; further larger sample prospective research is required to confirm these findings.
引用
收藏
页数:12
相关论文
共 42 条
  • [1] 2018 Alzheimer's disease facts and figures
    不详
    [J]. ALZHEIMERS & DEMENTIA, 2018, 14 (03) : 367 - 425
  • [2] Review and Meta-Analysis of Biomarkers and Diagnostic Imaging in Alzheimer's Disease
    Bloudek, Lisa M.
    Spackman, D. Eldon
    Blankenburg, Michael
    Sullivan, Sean D.
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2011, 26 (04) : 627 - 645
  • [3] The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer's disease: a literature review
    Brand, Abby L. L.
    Lawler, Paige E. E.
    Bollinger, James G. G.
    Li, Yan
    Schindler, Suzanne E. E.
    Li, Melody
    Lopez, Samir
    Ovod, Vitaliy
    Nakamura, Akinori
    Shaw, Leslie M.
    Zetterberg, Henrik
    Hansson, Oskar
    Bateman, Randall J. J.
    [J]. ALZHEIMERS RESEARCH & THERAPY, 2022, 14 (01)
  • [4] Comprehensive Review on Alzheimer's Disease: Causes and Treatment
    Breijyeh, Zeinab
    Karaman, Rafik
    [J]. MOLECULES, 2020, 25 (24):
  • [5] Revisiting the framework of the National Institute on Aging-Alzheimer's Association diagnostic criteria
    Carrillo, Maria C.
    Dean, Robert A.
    Nicolas, Francois
    Miller, David S.
    Berman, Robert
    Khachaturian, Zaven
    Bain, Lisa J.
    Schindler, Rachel
    Knopman, David
    [J]. ALZHEIMERS & DEMENTIA, 2013, 9 (05) : 594 - 601
  • [6] Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias
    Chetelat, Gael
    Arbizu, Javier
    Barthel, Henryk
    Garibotto, Valentina
    Law, Ian
    Morbelli, Silvia
    van de Giessen, Elsmarieke
    Agosta, Federica
    Barkhof, Frederik
    Brooks, David J.
    Carrillo, Maria C.
    Dubois, Bruno
    Fjell, Anders M.
    Frisoni, Giovanni B.
    Hansson, Oskar
    Herholz, Karl
    Hutton, Brian F.
    Jack, Clifford R., Jr.
    Lammertsma, Adriaan A.
    Landau, Susan M.
    Minoshima, Satoshi
    Nobili, Flavio
    Nordberg, Agneta
    Ossenkoppele, Rik
    Oyen, Wim J. G.
    Perani, Daniela
    Rabinovici, Gil D.
    Scheltens, Philip
    Villemagne, Victor L.
    Zetterberg, Henrik
    Drzezga, Alexander
    [J]. LANCET NEUROLOGY, 2020, 19 (11) : 951 - 962
  • [7] The neuropathological diagnosis of Alzheimer's disease
    DeTure, Michael A.
    Dickson, Dennis W.
    [J]. MOLECULAR NEURODEGENERATION, 2019, 14 (01)
  • [8] Revised NIA-AA criteria for the diagnosis of Alzheimer's disease: a step forward but not yet ready for widespread clinical use
    Frisoni, Giovanni B.
    Winblad, Bengt
    O'Brien, John T.
    [J]. INTERNATIONAL PSYCHOGERIATRICS, 2011, 23 (08) : 1191 - 1196
  • [9] The clinical use of structural MRI in Alzheimer disease
    Frisoni, Giovanni B.
    Fox, Nick C.
    Jack, Clifford R., Jr.
    Scheltens, Philip
    Thompson, Paul M.
    [J]. NATURE REVIEWS NEUROLOGY, 2010, 6 (02) : 67 - 77
  • [10] Clinical and cost implications of amyloid beta detection with amyloid beta positron emission tomography imaging in early Alzheimer's disease - the case of florbetapir
    Hornberger, John
    Bae, Jay
    Watson, Ian
    Johnston, Joe
    Happich, Michael
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (04) : 675 - 685